This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): GnRH Antagonist, NBI-56418
Description: NBI-56418 is an orally active, non-peptide GnRH inhibitor as an alternative to injected protein GnRH antagonists.
Deal Structure: Elagolix was originally developed by Neurocrine Biosciences.
In June 2010, Abbott and Neurocrine entered into a collaboration agreement to develop and commercialize elagolix for the treatment of endometriosis-related pain. In addition to endometriosis, elagolix will be evaluated for the treatment of uterine fibroids. Under the terms of the agreement, Abbott will receive worldwide exclusive rights to develop and commercialize elagolix and all next-generation GnRH antagonists for women's and men's health. Abbott will make an upfront payment of $75 million and will fund all ongoing development activities. Neurocrine is eligible to receive additional milestone payments of approximately $500 million from Abbott for the achievement of certain development, regulatory and commercial milestones; funding for certain internal collaboration expenses; plus royalty payments on any future product sales.
Partners: Neurocrine Biosciences, Inc.
Additional information available to subscribers only: